| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 0450 |
Emergency room services |
78,944 |
70,685 |
$13.34M |
| 99199 |
Unlisted special service, procedure or report |
51,361 |
43,398 |
$10.67M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
8,530 |
8,201 |
$5.34M |
| 70450 |
Computed tomography, head or brain; without contrast material |
9,727 |
9,330 |
$4.26M |
| 72125 |
Computed tomography, cervical spine; without contrast material |
4,135 |
3,996 |
$3.20M |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
14,157 |
12,707 |
$2.26M |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
1,750 |
1,691 |
$1.77M |
| 80053 |
Comprehensive metabolic panel |
62,661 |
56,200 |
$1.69M |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
6,786 |
6,637 |
$1.59M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
16,161 |
14,929 |
$1.55M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
10,863 |
9,991 |
$1.32M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
26,422 |
24,527 |
$1.25M |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
4,924 |
4,745 |
$1.20M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
15,261 |
12,801 |
$1.14M |
| 0250 |
|
18,116 |
7,550 |
$1.05M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
73,211 |
64,214 |
$1.03M |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
12,612 |
12,032 |
$981K |
| 82077 |
|
8,060 |
7,310 |
$948K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
3,738 |
3,674 |
$872K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
7,314 |
5,951 |
$872K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
17,761 |
12,012 |
$800K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
10,208 |
9,066 |
$750K |
| J3490 |
Unclassified drugs |
46,458 |
23,237 |
$700K |
| 71045 |
Radiologic examination, chest; single view |
16,504 |
15,632 |
$691K |
| 72131 |
|
1,457 |
1,427 |
$658K |
| 0762 |
|
1,536 |
590 |
$635K |
| 71046 |
Radiologic examination, chest; 2 views |
14,472 |
13,960 |
$620K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
1,150 |
1,123 |
$583K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
1,638 |
1,604 |
$578K |
| 96376 |
|
1,635 |
1,216 |
$533K |
| 80143 |
|
4,778 |
4,390 |
$485K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
11,734 |
9,717 |
$473K |
| 80179 |
|
4,660 |
4,310 |
$462K |
| 70486 |
|
729 |
720 |
$461K |
| 84484 |
|
23,883 |
17,074 |
$450K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
4,145 |
4,009 |
$444K |
| 0160 |
|
567 |
374 |
$428K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,650 |
1,506 |
$426K |
| 93971 |
|
2,200 |
2,126 |
$417K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,302 |
3,748 |
$411K |
| T1999 |
Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" |
16,198 |
7,868 |
$406K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
3,790 |
3,559 |
$402K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
3,375 |
3,279 |
$401K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,114 |
3,008 |
$383K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,514 |
2,286 |
$367K |
| 0270 |
|
12,265 |
6,586 |
$353K |
| 83690 |
|
23,171 |
21,378 |
$338K |
| Z7502 |
|
9,027 |
8,950 |
$329K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
444 |
438 |
$315K |
| 76830 |
Ultrasound, transvaginal |
2,625 |
2,551 |
$314K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
467 |
462 |
$307K |
| 70498 |
|
640 |
630 |
$301K |
| 70496 |
|
596 |
587 |
$256K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,420 |
1,000 |
$250K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
7,105 |
6,569 |
$249K |
| 83880 |
|
5,511 |
5,165 |
$242K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
17,652 |
15,550 |
$236K |
| 87040 |
|
9,186 |
5,839 |
$225K |
| 76801 |
|
2,118 |
1,880 |
$225K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
16,759 |
15,809 |
$220K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
3,416 |
3,364 |
$188K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
5,248 |
3,065 |
$185K |
| 81001 |
|
27,707 |
25,852 |
$182K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
3,092 |
998 |
$180K |
| 99499 |
|
2,850 |
2,345 |
$177K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
357 |
351 |
$171K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,328 |
2,256 |
$171K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,317 |
2,245 |
$168K |
| 82803 |
|
5,110 |
4,542 |
$168K |
| 72128 |
|
331 |
325 |
$160K |
| 73630 |
|
2,975 |
2,895 |
$156K |
| 73610 |
|
2,633 |
2,583 |
$154K |
| 73030 |
|
2,184 |
2,099 |
$153K |
| 71250 |
|
344 |
333 |
$151K |
| 83605 |
|
7,858 |
6,231 |
$145K |
| 0510 |
|
2,212 |
1,755 |
$142K |
| 73130 |
|
1,967 |
1,906 |
$139K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
1,325 |
1,192 |
$137K |
| 84443 |
Thyroid stimulating hormone (TSH) |
4,726 |
4,557 |
$137K |
| 83735 |
|
10,795 |
9,854 |
$131K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
950 |
930 |
$130K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
396 |
393 |
$116K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,631 |
1,363 |
$111K |
| 81025 |
|
9,211 |
8,904 |
$108K |
| 86850 |
|
2,425 |
2,312 |
$108K |
| 85730 |
|
5,570 |
5,244 |
$107K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
10,959 |
9,202 |
$107K |
| 0360 |
|
489 |
285 |
$103K |
| 73110 |
|
1,499 |
1,430 |
$103K |
| 93970 |
|
348 |
343 |
$102K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,072 |
1,053 |
$100K |
| 73562 |
|
1,836 |
1,774 |
$99K |
| 70491 |
|
216 |
213 |
$99K |
| 85610 |
|
9,968 |
9,246 |
$98K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
9,015 |
8,516 |
$94K |
| 85379 |
|
4,521 |
4,363 |
$85K |
| 87486 |
|
1,075 |
1,063 |
$83K |
| 87581 |
|
1,074 |
1,063 |
$83K |
| 84702 |
|
5,877 |
5,356 |
$82K |
| 90715 |
|
967 |
955 |
$79K |
| 86901 |
|
4,445 |
3,816 |
$79K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
6,580 |
5,979 |
$78K |
| 86900 |
|
4,586 |
3,723 |
$77K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
4,655 |
3,565 |
$73K |
| J2785 |
Injection, regadenoson, 0.1 mg |
183 |
181 |
$70K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
6,205 |
5,780 |
$69K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
734 |
723 |
$68K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
215 |
212 |
$66K |
| 81003 |
|
14,345 |
13,646 |
$64K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
4,453 |
3,826 |
$63K |
| 93017 |
|
483 |
480 |
$56K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,468 |
1,228 |
$55K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
3,917 |
3,337 |
$54K |
| 76770 |
|
333 |
326 |
$53K |
| 73080 |
|
717 |
698 |
$51K |
| 73502 |
|
583 |
565 |
$49K |
| 73560 |
|
787 |
747 |
$49K |
| 76497 |
|
18 |
17 |
$48K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
698 |
509 |
$46K |
| Z9725 |
|
1,454 |
1,440 |
$45K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
4,723 |
3,960 |
$45K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
316 |
312 |
$44K |
| 84703 |
|
8,889 |
8,516 |
$44K |
| 73590 |
|
615 |
599 |
$42K |
| 97750 |
|
366 |
298 |
$42K |
| 72100 |
|
773 |
751 |
$40K |
| 87077 |
|
3,954 |
3,607 |
$37K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
292 |
188 |
$36K |
| 87186 |
|
3,712 |
3,458 |
$35K |
| 76870 |
|
335 |
324 |
$34K |
| 82550 |
|
2,881 |
2,385 |
$33K |
| J2060 |
Injection, lorazepam, 2 mg |
2,860 |
2,402 |
$32K |
| 82552 |
|
1,300 |
1,045 |
$31K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,828 |
2,443 |
$31K |
| 80076 |
|
939 |
923 |
$30K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
3,014 |
2,707 |
$30K |
| 87634 |
|
300 |
294 |
$30K |
| 84145 |
|
851 |
829 |
$28K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
2,212 |
2,035 |
$28K |
| 73090 |
|
363 |
358 |
$26K |
| 74018 |
|
686 |
649 |
$25K |
| 84132 |
|
880 |
757 |
$24K |
| 82330 |
|
945 |
837 |
$23K |
| 86140 |
|
2,417 |
2,305 |
$23K |
| 87081 |
|
1,541 |
1,495 |
$21K |
| 72141 |
|
25 |
25 |
$21K |
| G0378 |
Hospital observation service, per hour |
425 |
319 |
$20K |
| 82947 |
|
2,489 |
2,221 |
$19K |
| 96367 |
|
292 |
235 |
$19K |
| 36415 |
Collection of venous blood by venipuncture |
16,822 |
14,474 |
$18K |
| 94644 |
|
497 |
471 |
$17K |
| 0760 |
|
258 |
222 |
$16K |
| 87400 |
|
1,570 |
1,469 |
$15K |
| 59025 |
Fetal non-stress test |
793 |
312 |
$15K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
683 |
613 |
$15K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
612 |
487 |
$15K |
| 0710 |
|
291 |
286 |
$14K |
| 99201 |
|
131 |
82 |
$13K |
| J1815 |
Injection, insulin, per 5 units |
796 |
463 |
$13K |
| 82150 |
|
175 |
174 |
$12K |
| 87430 |
|
693 |
661 |
$12K |
| S0028 |
Injection, famotidine, 20 mg |
534 |
467 |
$12K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
328 |
158 |
$11K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
709 |
692 |
$10K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
761 |
682 |
$9K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
13 |
13 |
$9K |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
340 |
196 |
$9K |
| 72170 |
|
29 |
29 |
$9K |
| 73700 |
|
25 |
25 |
$8K |
| 73140 |
|
238 |
236 |
$8K |
| 85652 |
|
1,996 |
1,922 |
$8K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
64 |
63 |
$8K |
| J3480 |
Injection, potassium chloride, per 2 meq |
130 |
85 |
$8K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
717 |
681 |
$7K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
390 |
380 |
$7K |
| 71020 |
|
166 |
52 |
$7K |
| S0164 |
Injection, pantoprazole sodium, 40 mg |
328 |
246 |
$6K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
668 |
603 |
$6K |
| A9585 |
Injection, gadobutrol, 0.1 ml |
56 |
51 |
$6K |
| J2704 |
Injection, propofol, 10 mg |
482 |
405 |
$5K |
| 73060 |
|
73 |
73 |
$5K |
| 87210 |
|
535 |
526 |
$5K |
| 84295 |
|
633 |
575 |
$4K |
| 10060 |
|
57 |
56 |
$4K |
| 93976 |
|
14 |
14 |
$4K |
| 73552 |
|
40 |
40 |
$4K |
| 87420 |
|
214 |
205 |
$3K |
| 80061 |
Lipid panel |
269 |
260 |
$3K |
| Z7610 |
|
363 |
172 |
$3K |
| 0324 |
|
15 |
15 |
$3K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
1,753 |
1,674 |
$3K |
| J3360 |
Injection, diazepam, up to 5 mg |
121 |
109 |
$3K |
| 84439 |
|
185 |
181 |
$3K |
| 72040 |
|
56 |
55 |
$3K |
| 87147 |
|
285 |
152 |
$3K |
| 29125 |
|
120 |
116 |
$3K |
| J7050 |
Infusion, normal saline solution, 250 cc |
207 |
147 |
$3K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
327 |
307 |
$3K |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
745 |
678 |
$2K |
| 87088 |
|
352 |
342 |
$2K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
34 |
34 |
$2K |
| J8540 |
Dexamethasone, oral, 0.25 mg |
928 |
574 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
88 |
88 |
$2K |
| 86308 |
|
218 |
217 |
$2K |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
936 |
879 |
$2K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
166 |
144 |
$2K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
72 |
67 |
$2K |
| 85027 |
|
252 |
200 |
$1K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
96 |
52 |
$1K |
| 84100 |
|
252 |
174 |
$1K |
| 12011 |
|
13 |
13 |
$1K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
344 |
157 |
$1K |
| 88300 |
|
121 |
119 |
$1K |
| 74022 |
|
13 |
13 |
$980.66 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
239 |
218 |
$974.69 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
51 |
42 |
$840.93 |
| 12001 |
|
25 |
25 |
$833.05 |
| 82010 |
|
57 |
51 |
$790.67 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
28 |
25 |
$699.93 |
| 72070 |
|
13 |
13 |
$612.18 |
| 99070 |
|
19 |
12 |
$576.10 |
| J1630 |
Injection, haloperidol, up to 5 mg |
42 |
39 |
$467.09 |
| S0077 |
Injection, clindamycin phosphate, 300 mg |
14 |
14 |
$424.05 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
74 |
62 |
$412.25 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
45 |
32 |
$388.52 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
16 |
12 |
$373.08 |
| 87205 |
|
44 |
38 |
$346.98 |
| 81015 |
|
60 |
60 |
$334.67 |
| 29515 |
|
13 |
13 |
$319.08 |
| 87070 |
|
14 |
12 |
$246.24 |
| 84550 |
|
40 |
37 |
$227.73 |
| 82270 |
|
27 |
27 |
$175.68 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
19 |
17 |
$170.38 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
60 |
52 |
$74.60 |
| 86592 |
|
13 |
13 |
$47.48 |
| 83550 |
|
12 |
12 |
$27.28 |
| 83540 |
|
12 |
12 |
$23.20 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
19 |
17 |
$0.00 |